Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23327)	7/17/1998 10:48:00 PM
From: Hippieslayer	Read Replies (2) \| Respond to of 32384

Which 5 drugs should be on the market by next year? And what part part of 99 do you see all 5 taking up a lot of space on the pharmaceutical shelves?

To: Henry Niman who wrote (23327)	7/18/1998 1:01:00 AM
From: bob zagorin	Read Replies (2) \| Respond to of 32384

henry, i have followed and owned quite a few biotechs and i will say that LGND has done an excellent job of financing their research and development stage. Many stocks I know have done additional stock offerings almost every year. I just can't understand why all these people who hate LGND and it's management so much bother to stick around the stock or this thread. I appreciate a certain amount of contrary opinion but, really, when i lose faith in mgt. or a company's business or research i take my losses and move on.

To: Henry Niman who wrote (23327)	7/19/1998 12:14:00 AM
From: Proton	Read Replies (2) \| Respond to of 32384

Re: Be Careful! By then end of next year LGND will have 5 drugs on the market and about double that number in the clinic. 15 X $300 million = $4.5 Billion and there are many more in preclinical testing. Those who think that the payment for the development of these drugs will somehow magically appear are either very naive or just not thinking things through. The same arithmetic can be used to excoriate LGND enthusiasts, Dr. Why sit and hold a stock with such an obviously voracious appetite for cash? At some point, the business model of LGND must shift from "depending on the kindness of strangers" to utilizing cash flow from sales and royalties to develop new drugs. I submit two points: 1. Until the business model can meaningfully shift (a bigger product than ONTAK or KS therapies), this stock will not realize the potential of its science or clinical pipeline. 2. There will be plenty of long-term money to be made once the shift has occurred. One might have to ride the stock from, say, 45 instead of 12, but that is worth the reduced risk. Pý (trying not to be too "parasitical")